Affinity Asset Advisors »

Kyverna Therapeutics shares owned by Affinity Asset Advisors

Quarter-by-quarter ownership of Kyverna Therapeutics (KYTX) shares owned by Affinity Asset Advisors from 13F filings

Historical chart of Affinity Asset Advisors investment in Kyverna Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Kyverna Therapeutics held by Affinity Asset Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Kyverna Therapeutics by Affinity Asset Advisors

Quarter filed Position value Share count Share price at filing
2024-06-30 $1.5M 200k 7.50

More positions owned by Affinity Asset Advisors

Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Teva Pharmaceutical Inds Sponsored Ads (TEVA)
Xenon Pharmaceuticals (XENE)
Apogee Therapeutics (APGE)
Madrigal Pharmaceuticals (MDGL)
Cerevel Therapeutics Hldng I (CERE)
Arcellx Common Stock (ACLX)
Crinetics Pharmaceuticals In (CRNX)
Nurix Therapeutics (NRIX)
Celldex Therapeutics Com New (CLDX)
Bridgebio Pharma Note 2.500% 3/1 (Principal)
Alnylam Pharmaceuticals Note 1.000% 9/1 (Principal)
Beigene Sponsored Adr (BGNE)
Alkermes SHS (ALKS)
Nuvalent Inc-a (NUVL)

View all positions for Affinity Asset Advisors

Top funds holding Kyverna Therapeutics

Vida Ventures Advisors
Bain Capital Life Sciences Investors
Northpond Ventures
Jpmorgan Chase & Co
Deerfield Management Company
Novo A/S
BlackRock
Vanguard Group
Millennium Management
Insight Holdings
Franklin Resources
T. Rowe Price Associates
Casdin Capital
Dr. Jeffrey R. Jay, M.D.
EcoR1 Capital

View all funds holding Kyverna Therapeutics